TB-500 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
== Signs and symptoms == The most common sign of hypospermia is a low volume of semen during ejaculation. The diagnosis is confirmed when one has a semen volume of less than 2.0 mL on at least two successive spermograms. If hypospermia is caused by retrograde ejaculation, sign include cloudy urine after orgasm. There may not be any symptoms of hypospermia unless it is caused by an abnormality.
2-Amino-3-carboxymuconic semialdehyde is an intermediate in the metabolism of tryptophan in the kynurenine pathway. Quinolinic acid is a neurotoxin formed nonenzymatically from 2-amino-3-carboxymuconic semialdehyde in mammalian tissues. 2-Amino-3-carboxymuconic semialdehyde is enzymatically converted to picolinic acid via 2-aminomuconic semialdehyde.
India–United States relations have improved significantly during the Premiership of Narendra Modi since 2014. At present, India and the US share an extensive and expanding cultural, strategic, military, and economic relationship which is in the phase of implementing confidence building measures (CBM) to overcome the legacy of trust deficit – brought about by adversarial US foreign policies and multiple instances of technology denial – which have plagued the relationship over several decades. Key recent developments include the rapid growth of India's economy, closer ties between the Indian and American industries especially in the Information and communications technology (ICT), engineering and medical sectors, an informal entente to manage an increasingly assertive China, robust cooperation on counter-terrorism, the deterioration of U.S.-Pakistan relations, easing of export controls over dual-use goods & technologies (99% of licenses applied for are now approved), and reversal of long-standing American opposition to India's strategic program. Income creation in the USA through knowledge-based employment by Asian Indians has outpaced every other ethnic group according to U.S. Census data. Growing financial and political clout of the affluent Asian Indian diaspora is noteworthy. Indian American households are the most prosperous in the US with a median revenue of US$100,000 and are followed by Chinese Americans at US$65,000. The average household revenue in the USA is US$63,000.
Sources: en.wikipedia.org
The concept of in situ in contemporary art developed in the late 1960s and 1970s, referring to works created for a specific site. Such works incorporate the site's physical, historical, political, and sociological characteristics as integral elements of their composition. This approach contrasts with autonomous artistic production, where artworks are conceived independently of their display location. Theoretical discussions, particularly in the writings and practice of French conceptual artist and sculptor Daniel Buren, have addressed the dynamic relationship between artistic intervention and its surrounding environment. The site-specific installations of Christo and Jeanne-Claude exemplify the application of in situ principles in art. Their large-scale interventions such as The Pont Neuf Wrapped (1985) and Wrapped Reichstag (1995) involved the systematic wrapping of buildings and landscape elements in fabric, temporarily transforming familiar spaces and altering public perception. Another example is the land art movement, wherein artists such as Robert Smithson and Michael Heizer integrated their works directly into natural landscapes. In contemporary aesthetic discourse, in situ describes practices that reinforce the fundamental unity between an artwork and its site.
== Applications == Desalting is used to remove salts from protein solutions, phenol or unincorporated nucleotides from nucleic acids or excess crosslinking or labeling reagents from conjugated proteins. Buffer exchange is used to transfer a protein solution into a buffer system appropriate for downstream applications such as ion exchange, electrophoresis or affinity chromatography.
The tumultuous reception that Sfeir received not only signified a historic reconciliation between Maronites and Druze, who fought a war in 1983–1984, but underscored the fact that the banner of Lebanese sovereignty had broad multi-confessional appeal and was a cornerstone for the Cedar Revolution in 2005. For historical and political reasons, social and economic conditions vary among Lebanon's sects. Christians in Beirut dominated the most lucrative financial and commercial sectors, while Muslims had a significant presence in lower value-added industrial sectors. Muslims generally comprised the majority of the working class, while Christians predominated in the middle and upper classes (about 75%), also owning most small and medium-sized enterprises. Researcher Gordon observed that in 1980, the financial income of Christians was approximately 16% higher than that of the Druze and about 58% higher than that of the Shiites.
=== Labeling accuracy === Researchers at the University of Adelaide found in 2014 that almost 20 percent of herbal remedies surveyed were not registered with the Therapeutic Goods Administration, despite this being a condition for their sale. They also found that nearly 60 percent of products surveyed had ingredients that did not match what was on the label. Out of 121 products, only 15 had ingredients that matched their TGA listing and packaging. In 2015, the New York Attorney General issued cease and desist letters to four major US retailers (GNC, Target, Walgreens, and Walmart) who were accused of selling herbal supplements that were mislabeled and potentially dangerous. Twenty-four products were tested by DNA barcoding as part of the investigation, with all but five containing DNA that did not match the product labels.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.